Open access
Aug 2026
Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF‐1α‐glycolysis axis to mediate anti‐PD‐1 resistance in non‐small cell lung cancer
CD155 is identified as a key driver of anti‐PD‐1 resistance in NSCLC and targeting CD155 combined with anti‐PD‐1 overcomes resistance, supporting a dual‐target therapeutic strategy.
Weiguang Du, Xi-Yang Tang, Yulong Zhou et al.
· Clinical and Translational M... · 0 citations